Table 4. Lesion specific age-adjusted prevalence for any HPV and HPV16 for each region.
| Age | Any HPV | HPV16 | Region | Any HPV | HPV16 | |
|---|---|---|---|---|---|---|
| Normal | <25 | 36.0(32.3–39.9) | 6.8(5.1–9.1) | Eastern | 33.1(31.6–34.5) | 4.5(4.0–5.3) |
| 25-<35 | 47.7(45.4–50.0) | 5.9(5.0–7.1) | Southern | 58.5(56.2–60.7) | 11.2(9.6–13.1) | |
| 35-<45 | 26.8(26.2–27.6) | 4.1(3.7–4.5) | Western | 28.7(27.1–30.8) | 4.2(3.5–5.0) | |
| 45-<55 | 25.3(23.8–26.9) | 3.7(3.2–4.5) | Middle | - | - | |
| = >55’ | - | - | Northern | 16.9(14.9–19.2) | 3.0(2.2–4.2) | |
| ASCUS | <25 | - | - | Eastern | 60.2(55.4–64.8) | 15.6(11.8–19.7) |
| 25-<35 | 65.0(58.6–71.0) | 6.6(4.0–10.7) | Southern | 62.7(55.7–69.2) | 6.3(3.8–10.1) | |
| 35-<45 | 41.2(37.9) | 13.5(11.3–16.1) | Western | 29.6(23.8–36.3) | 1.7(0.9–3.3) | |
| 45-<55 | - | - | Middle | - | - | |
| = >55’ | - | - | Northern | - | - | |
| LSIL | <25 | 100(0–100) | 10.0(2.5–32.4) | Eastern | - | - |
| 25-<35 | 76.0(72.6–79.0) | 16.8(14.2–19.8) | Southern | - | - | |
| 35-<45 | 70.8(67.4–73.9) | 10.8(8.7–13.2) | Western | - | - | |
| 45-<55 | 100(0–100) | 100(0–100) | Middle | - | - | |
| = >55’ | - | - | Northern | - | - | |
| HSIL | <25 | 100.0(0–100) | 5.6(0.7–3.1) | Eastern | - | 27.2(17.3–40.0) |
| 25-<35 | 81.5(77.7–84.7) | 28.6(24.7–32.8) | Southern | - | 28.9(18.2–42.7) | |
| 35-<45 | 80.0(73.1–85.4) | 31.8(29.1–34.7) | Western | - | 26.2(14.5–42.7) | |
| 45-<55 | 85.6(57.2–96.4) | 64.3(37.6–84.3 | Middle | - | - | |
| = >55’ | - | - | Northern | - | - | |
| ICC | <25 | - | - | Eastern | 91.4(89.9–92.9) | - |
| 25-<35 | 91.7(89.4–93.6) | 47.5(43.7–51.3) | Southern | 82.1(77.3–86.0) | - | |
| 35-<45 | 88.2(86.2–90.0) | 47.2(44.3–50.2) | Western | 87.3(84.4–89.7) | - | |
| 45-<55 | 91.1(89.7–92.4) | 52.8(50.4–55.1) | Middle | - | ||
| = >55’ | - | 49.9(45.7–54.1) | Northern | 89.0(85.2–91.9) | - |
'-' Age-group adjusted prevalence cannot be estimated because of sparse data.